CStone Pharmaceuticals — Board/Management Information 2019

Dec 6, 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [126 x 48] intentionally omitted <==

CStone Pharmaceuticals

基 石 藥 業

(Incorporated in the Cayman Islands with limited liability) ( Stock Code: 2616 )

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF MEMBER OF SENIOR MANAGEMENT

This announcement is made by CStone Pharmaceuticals (the “ Company ” or “ CStone ”) on a voluntary basis.

The board (the “ Board ”) of directors (the “ Directors ”) of the Company is pleased to announce that Ms. Shirley Zhao (“ Ms. Zhao ”) has been appointed as the General Manager for Greater China and Head of Commercial of the Company, primarily responsible for the commercialization of the Company’s products, with effect from December 9, 2019.

The biographical details of Ms. Zhao are set out below：

Ms. Zhao joined the Company on December 9, 2019 and serves as the General Manager for Greater China and Head of Commercial of the Company. Prior to joining the Company, Ms. Zhao served multiple multinational biopharmaceutical companies with over 26 years of experience with Chinese pharmaceutical market. From 2018 to 2019, she served as the general manager of China mainland and Hong Kong for Bristol-Myers Squibb (NYSE: BMY). From 2012 to 2018, she served as the country president of China at Allergan plc (NYSE: AGN). From 2009 to 2012, she served as the country general manager of China at Genzyme. From 2008 to 2009, she served as the commercial director of bioscience of Japan, China and North Asia at Baxter International Inc. (NYSE: BAX). From 1993 to 2008, she mainly focused on Oncology and successively served Bristol-Myers Squibb and Eli Lilly and Company (NYSE: LLY). From 1991 to 1993, she served as an obstetric and gynecologic physician of Shanghai Tenth People’s Hospital.

Ms. Zhao obtained her bachelor’s degree in medicine from Tongji University (同濟大學) in Shanghai, China in 1991. She also obtained an MBA degree from University of Leicester in the United Kingdom in 2001.

As of the date of this announcement, Ms. Zhao does not have any relationship with any director, senior management, substantial or controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company. Save as disclosed above, nor has she held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

1

The Board would like to take this opportunity to welcome Ms. Zhao on her new appointment.

By order of the Board CStone Pharmaceuticals Dr. Frank Ningjun Jiang Chairman

Shanghai, People’s Republic of China, December 6, 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and Executive Director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Guobin Zhang and Dr. Lian Yong Chen as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.

2